Potent JAK2, FLT3 and TrkA inhibitor (IC50
values are 0.9, 3 and < 25 nM respectively) that prevents STAT5 phosphorylation (IC50
= 20 - 30 nM). Exhibits antiproliferative activity in vitro
= 30 - 100 nM in HEL92.1.7 cells) and is effective against myeloproliferative disorders in vivo
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
The novel Trk receptor tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits antitumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness.
Miknyoczki et al.
Effect of FLT3 inhibition on normal hematopoietic progenitor cells.
Weisel et al.
Lestaurinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders.
Hexner et al.
The citations listed below are publications that use Tocris products. Selected citations for Lestaurtinib include:
Showing Results 1 - 2 of 2